Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752934 | 1.00 | CA12 (0.38) | CA12CA7CA14MGLLSMN1; SMN2 | |
| SCHEMBL1690915 | 0.97 | CA12 (0.36) | CA12CA7CA14MGLLSMN1; SMN2 | |
| SCHEMBL15916854 | 0.90 | PDK1 (0.33) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL8136165 | 0.87 | — | — | |
| SCHEMBL4622 | 0.87 | — | — | |
| Fluoride SCHEMBL28310400 | 0.87 | — | — | |
| SCHEMBL2123718 | 0.87 | CA12 (0.45) | CA12CA7CA14MGLLSMN1; SMN2 | |
| SCHEMBL1221354 | 0.87 | — | — | |
| SCHEMBL20614479 | 0.87 | CA12 (0.45) | CA12CA7CA14MGLLSMN1; SMN2 | |
| SCHEMBL10001930 | 0.87 | CA12 (0.45) | CA12CA7CA14MGLLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134226-A1 | BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013131901-A1 | BENZODIOXANES IN COMBINATION WITH OTHER ACTIVES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| WO-2013102655-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2013-07-11 | — | — | WO | disclosed |
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056070-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2012125598-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012107500-A1 | [1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096113-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FLT3, PDGFRB, PDGFRA | CA12 3823/4885CA7 3115/4885CA14 3532/4885 |
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | CA12 4673/4885CA7 4016/4885CA14 4634/4885 |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | CA12 4758/4885CA7 3705/4885CA14 4555/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | CA12 4763/4885CA7 4661/4885CA14 4745/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CA12 4583/4885CA7 4388/4885CA14 4651/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | CA12 4744/4885CA7 4721/4885CA14 4731/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | CA12 4763/4885CA7 4661/4885CA14 4745/4885 |
| US-20130196973-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTC4S | CA12 4793/4885CA7 4236/4885CA14 4501/4885 |
| US-20230203041-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | CA12 3881/4885CA7 3445/4885CA14 4546/4885 |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | CA12 4567/4885CA7 3665/4885CA14 4682/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | CA12 3257/4885CA7 4393/4885CA14 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.